News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
News Double IPOs headline this week's biotech financings This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici
News Sanofi eyeing pipeline deals ahead of Dupixent patent loss Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
